In a filing, Cytokinetics Inc revealed its President & CEO Blum Robert I unloaded Company’s shares for reported $0.25 million on Sep 15 ’25. In the deal valued at $49.77 per share,5,000 shares were sold. As a result of this transaction, Blum Robert I now holds 373,108 shares worth roughly $18.45 million.
Then, Malik Fady Ibraham sold 2,000 shares, generating $102,580 in total proceeds. Upon selling the shares at $51.29, the EVP Research & Development now owns 140,610 shares.
Before that, Kaye Edward M. MD sold 6,756 shares. Cytokinetics Inc shares valued at $337,800 were divested by the Director at a price of $50.00 per share. As a result of the transaction, Kaye Edward M. MD now holds 23,230 shares, worth roughly $1.15 million.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Monday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -3.31% to $49.44. Over the last five days, the stock has lost -5.09%. Cytokinetics Inc shares have fallen nearly -8.05% since the year began. Nevertheless, the stocks have risen 5.10% over the past one year.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-08-29, dropping by -1.69 million shares to a total of 13.83 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 15.52 million shares. There was a decline of -12.2%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
